How does intravenous immunoglobulin (IVIG) help in acute myocarditis and what are its side effects?

How Immunoglobulin Helps in Myocarditis

IVIG (2 g/kg) reduces mortality and improves cardiac function in acute myocarditis, particularly in children, by suppressing inflammatory cytokines and reducing oxidative stress, though evidence quality remains limited.

Mechanism of Action

IVIG works through multiple pathways in acute myocarditis:

• Anti-inflammatory effects: Suppresses inflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) 1
• Reduction of oxidative stress: Decreases plasma thioredoxin levels, which regulates cellular oxidative stress states 1
• Antiviral properties: Direct antiviral effects that may help clear viral pathogens triggering the myocarditis 1
• Immunomodulation: Modulates the autoimmune response that contributes to myocardial damage

Clinical Efficacy

Mortality Benefit

The most recent and highest quality evidence shows:

• In children: IVIG alone reduced in-hospital mortality (OR 0.24,95% CI 0.13-0.42) compared to steroids alone 2. The combination of IVIG plus steroids also showed benefit (OR 0.60,95% CI 0.42-0.87) 2
• Overall mortality reduction: Meta-analysis demonstrated IVIG reduced in-hospital mortality (RR 0.52,95% CI 0.35-0.76), long-term mortality (RR 0.5,95% CI 0.27-0.98), and overall mortality (RR 0.52,95% CI 0.34-0.76) 3
• Acute fulminant myocarditis: Significantly higher survival rate (OR 2.80,95% CI 1.16-6.77) 4

Cardiac Function Improvement

• LVEF improvement: Increased left ventricular ejection fraction by 6% (MD 6.00%, 95% CI 0.94-11.06) 3
• LVEDD reduction: Decreased left ventricular end-diastolic diameter (MD -3.77,95% CI -7.02 to -0.52) 3
• Rapid functional recovery: One study showed LVEF improved from 19% to 35.4% within approximately 12 days 1

Important Caveat

A Cochrane review found uncertain evidence in adults, with contradictory results between trials 5. However, the pediatric evidence is more consistent, and the most recent 2026 study strongly supports IVIG use in children 2.

Dosing Protocol

Standard dose: 2 g/kg based on ideal body weight, given as a single infusion 6

Modified dosing for cardiac dysfunction:

• Assess cardiac function and fluid status before administration 6
• If depressed cardiac function present: divide dose to 1 g/kg daily over 2 consecutive days 6
• Consider diuretics with administration to prevent volume overload 6

Do NOT give a second dose if refractory disease develops—risk of volume overload and hemolytic anemia outweighs potential benefit 6

Side Effects

Common Side Effects (FDA Label)

• Slight soreness at injection site 7
• Mild temperature elevation 7
• Pain and tenderness at injection site with overdose 7

Serious but Rare Side Effects

Volume-related complications (most important in myocarditis patients):

• Volume overload: Particularly dangerous in patients with cardiac dysfunction 6
• Hemolytic anemia: Risk increases with high doses and repeat dosing 6, 8
  • One case report documented severe hemolytic anemia in a child with myocarditis after high-dose IVIG 8

Hypersensitivity reactions (extremely rare):

• Angioneurotic edema 7
• Anaphylactic shock 7
• Nephrotic syndrome 7

Infusion-related side effects: Uncertain incidence but reported in trials 5

Risk Mitigation Strategies

1. Pre-treatment cardiac assessment mandatory: Check ejection fraction and volume status before infusion 6
2. Slow infusion rate in patients with cardiac dysfunction 6
3. Monitor for hemolysis: Especially with high doses or if considering repeat dosing
4. Avoid second doses: Use alternative intensification strategies (high-dose steroids or anakinra) for refractory disease 6
5. Consider divided dosing: Split into 1 g/kg over 2 days if cardiac function is compromised 6

Clinical Context

While guidelines specifically address MIS-C (multisystem inflammatory syndrome in children) 6, the principles apply to acute viral myocarditis. The most recent real-world evidence from 2026 analyzing 2,294 children shows IVIG use has actually decreased over time despite its association with improved survival 2. This suggests potential underutilization of an effective therapy, though a 2025 systematic review noted the absence of high-quality RCTs in children 9.